Integrated histology for quantitative digital pathology

Tissue-based biomarker investigation is a key step in pre-clinical / clinical drug development as it can serve either identification of novel therapeutic target, assessment of a surrogate marker of drug efficacy as well as prediction of a candidate compound benefit. To support novel therapies development at both pre-clinical and clinical level, we offer expert histology services relying on automated and standardized stainings capabilities spanning from monoplex to 7-plex marker panels and using either conventional chemistry or fluorescence revelation systems (immunohistochemistry/immunohistofluorescence).

Many types of samples – either tumor or normal tissue, originating from human or pre-clinical models – can be adressed using our platform. Multispectral images acquired on our PhenoImager HT (Akoya Biosciences) are processed through image analysis to provide quantitative data including phenotyping, marker expression, as well as geographical distribution of cells within the samples. In addition, bespoke services can also be offered to specifically meet our clients’ needs.

Illustrative data

Key advantages of tissue-based imaging

• Exploration at multiple scales, from cell-to-cell interactions to the macroscopic tissue architecture.
• Well-suited for simultaneous detection of multiple markers to identify specific cell subsets, document an immune response or quantify biomarkers of interest.
• Automated and robust workflow from sample processing to multiplexed image acquisition and quantification.